Примери за използване на Incidence of hypoglycaemia на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Incidence of hypoglycaemia at endpoint Bodyweight gain2.
Linagliptin alone showed a comparable incidence of hypoglycaemia to placebo.
The incidence of hypoglycaemia was similar across treatment groups.
Administration with a flexible dosing time had no effect on glycaemic control and the incidence of hypoglycaemia.
The incidence of hypoglycaemia was similar to placebo.
When sitagliptin was added to a sulphonylurea, the incidence of hypoglycaemia was increased over that of placebo(see section 4.8).
The incidence of hypoglycaemia was also similar in patients treated with sitagliptin or placebo.
When BYETTA was used in combination with a thiazolidinedione, the incidence of hypoglycaemia was similar to that of placebo in combination with a thiazolidinedione.
The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group(22.9% vs. 29.6%).
When linagliptin was added to a sulphonylurea on a background of metformin, the incidence of hypoglycaemia was increased over that of placebo.
In these studies the incidence of hypoglycaemia was similar for BYETTA and insulin treatment.
The incidence of hypoglycaemia was greater when alogliptin was used as triple therapy with pioglitazone and metformin(compared to active-control).
When immediate-release exenatide was used in combination with a thiazolidinedione, the incidence of hypoglycaemia was similar to that of placebo in combination with a thiazolidinedione.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo.
When exenatide was used in combination with metformin alone,no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin which may be due to this glucose-dependent insulinotropic mechanism.
The incidence of hypoglycaemia was not significantly different between the treatment groups(sitagliptin, 1.3%; metformin, 1.9%).
In this study there was a similar incidence of hypoglycaemia reported for patients treated with sitagliptin or placebo.
The incidence of hypoglycaemia was not significantly different between the treatment groups(sitagliptin, 6.3%; glipizide, 10.8%).
In these studies there was a similar incidence of hypoglycaemia reported for patients treated with sitagliptin or placebo.
The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the vildagliptin and placebo groups, respectively.
In a clinical trial of alogliptin as mono-therapy, the incidence of hypoglycaemia was similar to that of placebo, and lower than placebo in another trial as add-on to a sulphonylurea.
The incidence of hypoglycaemia in the linagliptin group(7.5%) was significantly lower than that in the glimepiride group(36.1%).
In these studies the incidence of hypoglycaemia was similar for immediate-release exenatide and insulin treatment.
The incidence of hypoglycaemia in the overall population was 4.7% and 5.6% in the vildagliptin and placebo groups, respectively.
In clinical trials, the incidence of hypoglycaemia was uncommon in patients receiving vildagliptin+ pioglitazone(0.6%) but common in patients receiving placebo+ pioglitazone(1.9%).
The incidence of hypoglycaemia episodes/events with canagliflozin 300 mg and sitagliptin 100 mg was 40.7% and 43.2%, respectively.
The observed incidence of hypoglycaemia in patients treated with sitagliptin was similar to placebo.
The incidence of hypoglycaemia was low(1.4%) in subjects treated with saxagliptin plus dapagliflozin plus metformin group.
The incidence of hypoglycaemia in the sitagliptin group(6.2%) was significantly lower than that in the glipizide group(17.0%).
The incidence of hypoglycaemia in the sitagliptin group(4.9%) was significantly lower than that in the glipizide group(32.0%).